ConductScience.org, home
Open Label Controlled Trial of Eculizumab in Adult Patients With Plasma Therapy-sensitive Atypical Hemolytic Uremic Syndrome (aHUS)
API referenceFor AI assistants

Trial · NCT00838513

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

1 to 16 of 16

Download this page as JSON
OutcomeGroupCategoryValueSpreadUnits
Percentage of Patients With TMA Event-free StatusEculizumab8095% Confidence Interval 56 to 94Percentage of Participants
Percentage of Patients With Hematologic NormalizationEculizumab9095% Confidence Interval 68 to 99Percentage of Participants
Percentage of Patients With Complete TMA ResponseEculizumab2595% Confidence Interval 9 to 49Percentage of Participants
TMA Intervention RateEculizumab0Standard Deviation 0#events/patient/day
Platelet Count Change From Baseline to 26 WeeksEculizumab6.7595% Confidence Interval -15.73 to 29.2310^9 cells/L
Percentage of Patients With Platelet Count NormalizationEculizumab9095% Confidence Interval 68 to 99Percentage of Participants
Percentage of Patients With TMA Event-free StatusEculizumab9595% Confidence Interval 75 to 100Percentage of Participants
Percentage of Patients With Hematologic NormalizationEculizumab9095% Confidence Interval 68 to 99Percentage of Participants
Percentage of Patients With Complete TMA ResponseEculizumab5595% Confidence Interval 32 to 77Percentage of Participants
TMA Intervention RateEculizumab0.00Standard Deviation 0.02#events/patient/day
Platelet Count Change From Baseline to 156 WeeksEculizumab-3.6895% Confidence Interval -25.15 to 17.7910^9 cells/L
Percentage of Patients With Platelet Count NormalizationEculizumab9095% Confidence Interval 68 to 99Percentage of Participants
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood ConcentrationEculizumabmax concentration during induction period161.47Standard Deviation 27.29micrograms/mil
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood ConcentrationEculizumabmin concentration during induction period112.43Standard Deviation 16.98micrograms/mil
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood ConcentrationEculizumabmax concentration during maintenance427.48Standard Deviation 67.54micrograms/mil
Pharmacokinetics (PK) and Pharmacodynamics (PD); Minimum and Maximum Blood ConcentrationEculizumabmin concentration during maintenance212.45Standard Deviation 53.75micrograms/mil

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00838513/results

API referenceFor AI assistants